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Local Anesthetics Infiltration and 
Wound Healing Process
João Abrão, Marcelo Antunes and Luis Vicente Garcia
Abstract
It is a good practice, nowadays, to infiltrate local anesthetics along the inci-
sion to prevent postoperative pain. This can reduce the use of opioids and the side 
effects they cause. It is known clearly that the surgical trauma causes inflammatory 
reaction, and this can be the beginning of a bad cicatrization or even a scar. The 
use of local anesthetics preventing the acute pain is a very simple technique and 
has proved to be useful. Nevertheless, the reaction that various anesthetics have 
over the tissues and the cicatrization process is yet controversial and deserves to 
be investigated deeply. The use of different formulations of these drugs has been 
stimulated. The duration and secureness have been the goals of many researches. 
Levobupivacaine, ropivacaine, and bupivacaine for their long action; lidocaine for 
less toxicity; and liposomal formulation for the longest duration ever seen, all of 
them have been indicated in the postoperative pain management. The aim of this 
chapter is to evaluate the role of long duration local anesthetics on the inflamma-
tory reaction and consequently the collagen production and resistance of the tissue 
to traction.
Keywords: local anesthetics, pharmacology, ropivacaine, bupivacaine, tensile 
strength, wound healing, drug effects
1.  Introduction (local anesthetics, general comments, classification 
regarding structure and duration)
Local anesthetics (LA) are widely used in clinical practice in anesthesiology. 
They possess the common property of transient interruption in the neural conduc-
tion, and in the fibers C and Aδ, they cause interruption of pain transmission. 
Pharmacologically, there is a selective blockade of Na+ channels [1, 2]. The mecha-
nism of action of LA is not related only to binding to the Na+ channels. LA have an 
important role in other targets (channels and receptors); for example, in K+ and 
Ca++ channels, they have an anti-inflammatory effect by bounding to G protein 
(inhibiting the adhesion of polymorphonuclear leukocytes, macrophages, and 
monocytes), increase the release of glutamate, as well as interfering in the activity 
of some intracellular signaling pathways [3, 4].
There are at least five applications for the use of LA in anesthesiology: local 
infiltration, regional intravenous anesthesia (Bier block), peripheral nerve block, 
central nervous system (CNS) blockade (spinal anesthesia, epidural, and caudal), 
and topical deposit (EMLA, eye drops in ophthalmology) [3]. In this chapter, we 
will discuss its application in the infiltration of the operative wound and its effects 
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in the inflammatory process, after a brief discussion about the pharmacological 
structure of LA.
2. Na+ channel structure: the main target of conventional LA
The Na+ channel is composed of one alpha subunit and one or two beta sub-
units, which can be present in three different states: resting, open, and inactivated 
(Figure 1). The AL binds to the Na+ channel after crossing the plasma membrane, 
that is, they bind to an internal portion of the alpha subunit preventing its activa-
tion and consequent depolarization of the membrane (Figure 2). Thus, the impulse 
is not propagated through the neurons, which prevents the perception of nocicep-
tive pain [5, 6].
3. Classification of AL (esters and amides and justify the use of each)
In its chemical structure, the LA are weak bases that possess in its molecule a 
lipophilic portion (aromatic ring) and another hydrophilic (tertiary amine) sepa-
rated by an intermediate chain (hydrocarbon chain containing an ester or an amide 
group) (Figure 3) [7, 8].
The latter allows the classification of LA in amino-esters or amino-amides. 
These two groups differ in relation to its biotransformation site (the ester forms 
are metabolized by plasmatic esterases, while amide forms are degraded by hepatic 
enzymes) [9, 10].
Figure 2. 
The electric stimuli are not able to open the Na+ channel because it is blocked by the LA.
Figure 1. 
Na+ channels—it opens with the voltage changes (depolarization) propagated by the electrical impulse.
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Regarding the allergenic potential—the para amino benzoic acid (PABA) is an 
allergenic metabolite of the amino esters. Caution must be observed with some LA 
formulations, because methylparaben and metabisulfite are allergenic used as a 
preservative [11].
The size of the alkyl chain, in the amino group or aromatic ring, confers the LA mol-
ecule its hydrophobic character and its permeability in the lipid bilayer. So, the larger 
the nitrogenated radicals will be their potency and duration of LA blockades [12].
4. LA toxicity
Followed by the application of AL in the patient, a fraction will be absorbed by 
the bloodstream (plasma). Depending on the dose administered, the LA may reach 
higher or lesser degree the noble organs (e.g., brain and heart) producing physi-
ological alterations in these tissues as well. The total dose used should comply with 
a maximum limit to try to avoid these undesirable effects, known as systemic LA 
toxicity [13]. Usually, in clinical practice, we must respect the maximum dose of 
each LA. Note that the CNS effects of lidocaine vary according to its plasma concen-
tration (Table 1)—the higher the plasma concentration, the greater the risk to the 
patient, even develop a cardio-respiratory arrest. Thus, it is mandatory to observe 
the maximum allowable doses for each LA.
LA may also induce cardiac toxicity depending on the dose employed, acting 
directly in the heart (specialized conduction tissues) and decreasing the contractil-
ity of ventricular myocytes. Bupivacaine is more cardio depressor than lidocaine 
[14–16].
Figure 3. 
LA generic structural formula.
Plasma concentration (mcg/mL) Effect
1–5 Analgesia
5–10 Numbness of tongue, tinnitus
10–15 Seizures
15–25 Coma, respiratory failure
>25 CV depression
Table 1. 
CNS toxicity—lidocaine plasma concentrations and its effects [17].
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5.  Long-term local anesthetics: ropivacaine, bupivacaine, and 
levobupivacaine. (Pharmacological characteristics: concentration 
used in practice, toxic dose and care). Liposome formulations
The duration of action of LA is influenced by its effect on the vascular smooth 
muscle tone (vasoconstriction/vasodilatation) adjacent to the place where it is 
deposited. Other factors that determine its duration include the volume and con-
centration used, the approach itself (infiltrative versus regional peripheral nerve 
versus CNS blocks), the target tissue (fiber’s diameter and myelin sheath), and the 
plasma protein binding (drug-specific affinity).
Long-term LA are the most used in clinical practice in anesthesiology at the fol-
lowing maximal allowed doses—bupivacaine (2 mg/kg), levobupivacaine (2 mg/kg), 
and ropivacaine (3 mg/kg).
5.1 Bupivacaine
Bupivacaine is presented as a racemic mixture of enantiomers R+ and S−. The 
optical isometry due to the presence of a chiral carbon (asymmetric) confers several 
possibilities in the formulation of the LA.
Bupivacaine promotes differential conduction blockade. As it produces more 
sensory than motor blockade, it plays an important role in the postoperative pain 
control. The use of epinephrine (5 μg/mL) gives a small increase in its duration of 
action (as opposed to lidocaine, which takes great advantage over this association). 
The use of large volumes for infiltration should be taken with cautious and done 
gradually and intermittently (3–5 mL at 5 min intervals). The patient should always 
be monitored to detect any unintentional intravascular injection of LA. Bupivacaine 
presents a higher risk of cardiac toxicity, when compared to levobupivacaine and 
ropivacaine. Every injection of this anesthetic should be done with the utmost care, 
always checking the positioning of the needle (by aspirating the syringe ensuring 
that the needle bevel is not intravascular).
5.2 Levobupivacaine
This anesthetic is the S-isomer of the bupivacaine, having the advantage of less 
neuro-cardio-toxicity due to lower affinity for these tissues. From a cardiac point 
of view, it causes a shorter prolongation of the QT interval and lower negative 
inotropism than racemic or R+ bupivacaine [18]. Its analgesic profile is similar to 
bupivacaine, because its duration of action is also long-lasting. Like ropivacaine, it 
has an intrinsic vasoconstrictor effect.
5.3 Ropivacaine
It is an anesthetic formulated by the pure enantiomer S of 1-propyl 2′-6′ pipeco-
loxylide [19]. As levobupivacaine, it has a safer profile than bupivacaine, because it 
has a lower toxicity in the CNS and heart. Its duration of action is long-lasting, like 
that of bupivacaine and levobupivacaine. It is widely used in infiltrative anesthesia 
and peripheral nerve blocks in anesthesiology. The same precautions should be 
taken with the use (intermittent and monitored injections). It is worth remember-
ing that ropivacaine possesses intrinsic vasoconstrictor effect, which confers lower 
vascular absorption and increases its duration of action (levobupivacaine also owns 
this property).
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6. Liposomal formulations
New methods of releasing the LA have been used in order to prolong the analge-
sia conferred by these anesthetic drugs. One of them is to produce liposomes spheres 
loaded with LA. This system allows LA deposit in the center of the liposomes, being 
involved by a double lipid layer. This setting allows a slower, controlled, and gradual 
release of LA, (72–96 h), consequently providing extended analgesic duration 
[20–23]. Liposomal bupivacaine (LB) has a decreased spread when compared with 
conventional bupivacaine. Therefore, several injections are needed and next to 
each other to obtain better results. In the infiltrative technique, it should be injected 
continuously from the fascia to the dermis. Unlike conventional formulations, which 
use bupivacaine HCl, the LB is produced only with its unprotonated basic form.
7. Infiltrative or transdermal techniques: practical recommendations
When the LA is used to infiltrate the operative wound, the anesthesiologist 
should seek a balance between the dose employed considering the size of the area 
to be anesthetized. In other words, it is sought to dilute the total dose used to cover 
most of the tissues operated. Thus, the same amount of LA used for infiltration on 
one side (e.g., right breast) needs to be diluted (doubling the volume) and to be 
employed bilaterally (e.g., right and left breast), always keep in mind that we must 
respect the maximum safety doses.
This approach allows an alternative to single dose injection of LA, namely the 
implantation of catheters for complementary use of the medication (continuous 
and/or in bolus, known as Patient Controlled Analgesia PCA) in order to prolong its 
therapeutic effect. In clinical practice, these resources increase costs because they 
need to be supervised, in addition to the increased risk of infection at the catheter 
implant site. New approaches are being investigated to optimize postoperative 
analgesia—use of newer drugs, innovative delivery systems (liposomal bupivacaine 
and ropivacaine), and the use of adjuvants along with LA.
8.  Non-anesthetic drugs (adjuvants) injected together with LA 
(magnesium, epinephrine, clonidine, morphine, dexmedetomidine, 
and steroids). Is it worth?
With the advent of several approaches in the treatment of postoperative pain, 
the anesthesiologist can associate the use of various drugs and techniques aiming 
at greater efficacy in their control. The simultaneous use of several drugs (with 
pharmacological synergism) allows the anesthesiologist to decrease the total dose 
employed, when compared to the isolated use of each of them. This is one of the 
reasons for the use of adjuvants with the LA [24–26]. Another reason is to reduce 
opioid consumption in the post-operative period and associated collateral effects.
Usually, there is a consensus about the use of adjuvants in anesthesia, that is, the 
anesthesiologist must balance risks versus benefits and mainly the common sense. It 
is his/her responsibility to do the best choice in each case.
8.1 Magnesium
Magnesium sulfate antagonizes ionotropic N-methyl-D-aspartate (NMDA) 
glutamatergic receptor interfering in calcium homeostasis (membrane potential). 
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When injected together with LA in regional anesthesia, some evidence suggest that 
its use is beneficial [27]. Conversely, the use of magnesium sulfate intravenously is 
controversial [28, 29].
8.2 Dexmedetomidine
Dexmedetomidine (DMD) is a strong and highly selective α2-adrenoceptor 
agonist. When added to local anesthetics can enhance the analgesic efficacy of the 
peripheral regional nerve block [30]. DMD is eight times more selective than cloni-
dine. It has analgesic, sedative, and antihypertensive effects, when used in systemic 
route. This substance has been associated with bupivacaine and lidocaine aiming 
prolonging the analgesic effect [31].
8.3 Epinephrine
Epinephrine has been used mixed to local anesthetics since a long time ago, 
and its recommended concentration is 5–10 μg/mL. It has, besides vasoconstrictive 
action that prolongates the local anesthesia, an analgesic effect mediated by alpha-2 
adrenoceptor activation [32]. The vasoconstrictor effect of epinephrine can prevent 
inadvertent intravascular administration of local anesthetic solutions. Nowadays, 
the use of ultrasonography made such use largely redundant [33].
The onset time of local anesthesia after single injection was considered clinically 
significantly reduced when epinephrine was added to lidocaine or bupivacaine, 
when performing peripheral nerve blocks [34]. Current recommendations, how-
ever, allow the use of epinephrine in peripheral blocks only when ultrasonography 
is not available [35].
8.4 Clonidine
Clonidine applied at perineural sites, in doses up to 1.5 mcg/kg, acts as an adjuvant 
to local anesthetics prolonging analgesia and sensory/motor blocks [36]. It has intrinsic 
analgesic properties, inhibiting action potentials of C and Aδ fibers, as well as modu-
lates the redistribution of local anesthetics through alpha1-receptors activation [37].
Side effects of this drug are dose dependent and include sedation, by decreasing 
sympathetic outflow (suppressing the release of norepinephrine in locus ceruleus 
(CNS) and substantia gelatinosa), hypotension, bradycardia, dry mouth, constipa-
tion, dizziness, and drowsiness [38].
Clonidine represents a good addition for the armamentarium of anesthesiolo-
gists because it prolongs the duration of analgesia, provides a faster onset of action, 
and improves the quality of nerve blocks (decreasing opioid consumption) [39, 40].
8.5 Morphine
Morphine is used by several routes and dosages (intrathecal: 100–200 mcg, 
epidural: 1–5 mg, peripheral nerve block: 75–100 mcg/kg, intravenous and intra-
muscular) [41]. Despite its use to prolong the analgesia, it is important to the 
anesthesiologist to pay attention at recommended doses to avoid the undesirable 
side effects (pruritus, nausea, vomiting, urinary retention, and respiratory failure). 
Always double check the vials before the administration of this medication because 
there are several vials currently in use (2, 4, 5, 8, and 10 mg/ml). All vital signals 
must be monitored at post-anesthetic care unit after the morphine use to early 
detect any cardiovascular or respiratory complications: bradycardia, hypotension, 
hypoxemia, and respiratory failure [42].
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8.6 Steroids
Dexamethasone, a potent anti-inflammatory agent, has been investigated for 
its role as an adjuvant to local anesthetics in neuraxial as well as peripheral nerve 
blocks. This steroid has been used in intrathecal anesthesia (8 mg preservative 
free), in epidural analgesia (4–8 mg) and as an adjuvant in a variety of peripheral 
blocks, like brachial plexus, ankle block, and TAP block. A meta-analysis has found 
it to significantly prolong the duration of brachial plexus block when using con-
ventional local anesthetics solutions [43]. Besides all the researches about the role 
of dexamethasone in neural block, one question has not been answered yet: is the 
better and prolonged analgesia caused by systemic effects of the steroid?
9. The four stages of wound healing
The wound healing is a continuous process, but for didactic understanding, 
it can be divided into four phases [44, 45]. The first phase occurs just after the 
incision or lesion of the skin, as soon as the blood leaks out of the body. There is a 
vasoconstriction, and the platelets stick together to initiate the coagulation. This 
phase is called the hemostasis phase. The platelet plug is reinforced by threads of 
fibrin. The hemostasis phase occurs very rapidly, in a question of seconds. As the 
fibrin mesh is formed, the blood is transformed from liquid to a gel state, that is, the 
pro-coagulant effect of prothrombin. This clot keeps the platelets and blood cells 
trapped in the wound area. Just after the injury of the skin, the epidermal tissue and 
the keratinocytes release the interleukin-1 (IL-1) pre-stored in these sites. The coag-
ulation process activates the clotting cascade which is responsible to give the matrix 
for the influx of inflammatory cells. The degranulation of the platelets releases 
alpha granules, which secrete growth factors, like epidermal growth factor (EGF), 
platelet derived growth factor (PDGF), and transforming growth factor-beta (TGF-
β). The PDGF and the IL-1 are responsible for attracting neutrophils to the wound 
site to remove bacteria [44]. The monocytes cells are converted to macrophages 
by influence of TGF-β, what has an important role in the initiation of the granula-
tion tissue and a many proinflammatory cytokines (IL-1 and IL-6), besides other 
growth factors, like fibroblast growth factor (FGF), EGF, TGF-β, and PDGF. All 
these growth factors and the added endothelial cell proliferation ensues the angio-
genesis beginning. During this hemostasis phase, the injured blood vessels leak 
transudate causing localized swelling and cell migrations to the site of wound. The 
damaged cells, pathogens, and bacteria are removed. White cells, growth factors, 
nutrients, and enzymes create the swelling, heat, pain, and redness, normally seen 
in the wound healing. This phase where all these signs appear is called the inflam-
matory phase. This phase is not a problem unless it is prolonged and excessive. After 
all the bacteria and debris are removed, the wound is rebuilt with a new tissue made 
up of collagen and extracellular matrix. This is the proliferative phase. In this phase, 
new blood vessels are formed, so that the granulation tissue can receive enough 
oxygen and nutrients. The myofibroblasts are responsible for the contraction of the 
wound, making the granulation tissue to take the ideal dimensions to the lesion. The 
granulation in this phase is pink or red. If there is a dark color is a sign of infection, 
ischemia or poor perfusion. At the end of this process the epitelial cells resurface 
the wound extension, what is called the maturation or remodelling phase. In this 
stage, it is wise to maintain the wound moist and hydrated to optimize the epitheli-
alization [46]. Some authors consider that the wound healing has only three phases, 
and this is comprehensible as long as the hemostasis phase and the inflammatory 
phase are so concomitant, dynamic, and interactive, that they consider it just as an 
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inflammation phase. In fact, the phases do not have a predetermined duration, as 
Witte and Barbul showed in their article (Figures 4 and 5), the migration of cells to 
the wound site and the matrix formation [47].
10. Local anesthetics can influence the process of wound healing?
When there is a rupture of vessels, there is an exposure of the subendothelial 
collagen to the platelets. This contact results in the aggregation and activation of 
the intrinsic factor of coagulation cascade. In the presence of thrombin, fibro-
nectin, and their fragments, there is the release of cytokines and growth factors 
from platelets (PDGF), transforming growth factor-β (TGF-β), platelet-activating 
Figure 5. 
Deposition of wound matrix components over time [47].
Figure 4. 
The time course of different cells during healing process. Macrophages and neutrophils are predominant in 
inflammation phase, whereas lymphocytes peak somewhat later. In the proliferative phase, fibroblasts are more 
frequent [47].
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factor (PAF), fibronectin, and serotonin. All this form the local fibrin clot that is 
the scaffolding for invading cells such as neutrophils, monocytes, fibroblasts, and 
endothelial cells. The neutrophils are the first cells to invade the wound, increas-
ing the vascular permeability due to inflammation and release of prostaglandins. 
In the same time, chemotactic substances like complement factors, interleukin, 
tumor necrosis factor-α (TNF-α), TGF-β, platelet factor 4, and stimulate neutro-
phil migration [47–49]. The factors associated with wound healing can be seen in 
Table 2.
When analyzing the possible action of the LAs in the wound healing process, 
many aspects can take role. Injecting any substance in the surgery site, it is expected 
that it can have at least a pH influence, as the anesthetic has a pH different of the 
physiologic one. Many times, epinephrine is used to prolong the duration and lower 
the toxicity of the drug used [50, 51]. The influence of pain in the wound healing 
has been studied too [52–54]. The wound healing in the fetus has also been the 
object of research [55, 56]. And last, the LA probably can have a direct action in the 
eicosanoids or in the fibroblast formation and so in the cicatricial process [56].
These all are hypothesis that are discussed deeply, and many researches in 
human have to be done, unfortunately the majority of the manuscripts are in rats 
and they have a different immunologic system than humans.
The tissue injury caused by surgery produces directly and indirectly activa-
tion of nociceptors and higher expression of proinflammatory cytokines and 
cyclooxygenase-2 (COX-2), leading to peripheral and central sensitization with 
subsequent hyperalgesia. The pain and inflammation are maintained by abundant 
eicosanoids, like prostaglandin E2, released after surgical trauma. The long-acting 
local anesthetics such as bupivacaine and ropivacaine are used to provide prolonged 
perioperative pain relief and to diminish the occurrence of postoperative sensitiza-
tion that manifests with hyperalgesia after the anesthetic effect has dissipated. The 
occurrence of hyperalgesia is very common when high doses of anesthetic are used 
[57, 58]. The routine of infiltrating the surgical site reduces the postoperative pain 
and morbidity and accelerates the recovery. This can be explained by reducing the 
Function
Hemostatic factors
Fibrin, plasma fibronectin Coagulation, chemo attraction
Structure for cell migration
Factor XIII (fibrin-stabilizing 
factor)
Circulatory growth factors
Chemo attraction and adhesion
Modulation of chemo attraction, mitogenesis, fibroplasia
Complement Antimicrobial activity, chemo attraction
Platelet-derived factors
Cytokines, growth factors Regulation of chemo attraction, mitogenesis, fibroplasia
Fibronectin Early matrix, ligand for platelet aggregation
Platelet-activating factor (PAF)
Thromboxane A2
Platelet aggregation
Vasoconstriction, platelet aggregation, chemotaxis
Platelet factor IV Chemotactic for fibroblasts and monocytes, neutralizes activity of 
heparin, inhibits collagenase
Serotonin Induces vascular permeability, chemoattractant for neutrophils
Adenosine dinucleotide Stimulates cell proliferation and migration, induces platelet aggregation
Table 2. 
Hemostatic and platelet-derived factors associated with wound healing [47].
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production of cytokines. Although LA action is to block the nerve conduction, they 
have other cellular targets that modulate the inflammation, suggesting that the 
LAs have an anti-inflammatory effect [59, 60]. Several studies have shown that LA 
dose-dependently inhibits leukocyte adhesion to synthetic material and to blood 
vessel walls. LA can induce the release of prostacyclin, and this causes the release of 
leukocytes previously firmly adherent to vascular endothelium. It is shown that the 
LA can in low concentration stimulate the phospholipase A2 (PLA2) while in higher 
concentrations inhibited this enzyme [61].
All these considerations are important, but what is important in clinical aspects 
are the fibroblast formation and the quality of the wound healing. The first question 
the patient formulates is when he will return to normal life activity. To answer this 
question, it is important to have not only histological analyzes of the wound but also 
mechanical testing to be sure that the tissue is ready to normal work. Vasseur and 
cols in 1984 studied the effects of local anesthetics on abdominal wounds of rabbits 
[62]; using mechanical testing device, they could demonstrate that the breaking 
strength in the groups infiltrated with lidocaine or bupivacaine, do not vary con-
sistently from the tissues infiltrated with saline solution, and so they conclude that 
the local infiltration with lidocaine and bupivacaine does not alter substantially the 
healing of midline abdominal incisions in rabbits. Abrão and cols in 2014 made a 
similar work using rats and long-lasting anesthetics, bupivacaine, and ropivacaine 
[63]. They used a computerized universal testing machine, and they concluded 
that there were no significant differences among the groups with respect to tensile 
strength after 14 days. These results, however, are not the same than Hanci and cols 
in 2012, who found that lidocaine and bupivacaine reduce the collagen production 
and the wound breaking strength in Wistar rats [64]. To further augment the argu-
ment, Kesici and cols in 2018 studied the effect of bupivacaine, levobupivacaine, 
and procaine in the Sprague Dawley rats [65]. They found that bupivacaine and 
levobupivacaine affect negatively the wound healing, especially at the late period 
(21 days). The differences in these studies increase the uncertainty and discussion 
regarding the effects of local anesthetics. Many aspects must be considered like the 
animal gender, the use of other analgesic like paracetamol, the infiltration method, 
and the time of evaluation. Interestingly, there is no work done on humans, who 
certainly have a different response to pain. Probably, the reason is the difficulty to 
use the same methodology. All the researches in humans have only clinic evaluation, 
it is almost impossible to make mechanical tests. Uncertainties in this field only will 
be clarified with new studies. The clinical studies in human beings have a very sub-
jective way to follow the wound healing. They constitute another subject that must 
be studied separately. The analogic scale of pain as the consume of opioids has been 
used as parameters to analyze the efficacy of the method. These studies conclude 
that ropivacaine (0.3%) can be used alone or with the addition of DMD (1 μg/kg), 
and there is no effect on wound healing [31, 66]. We must bear in mind that some 
authors only used a clinic evaluation, what can vary a lot from one researcher to 
another.
11. Conclusion
Nowadays, all the anesthesiologists are engaged in avoiding the excessive use 
of opioids for their side effects in the postoperative pain treatment. In fact, the 
μ-opioid receptors are impaired by the unrestricted use of morphine like drugs, 
besides there is an inhibition of the beta-endorphin release. Considering that the 
infiltration of LA in the surgical site does not produce, clinically any significant 
harm to the tissue cicatrization, and has the property of sparing opioid use, this 
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